Sanofi: NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases.
Read full article »
Sanofi is a France-based healthcare firm that develops and markets pharmaceutical drugs and OTC medicines for the treatment of a range of diseases such as diabetes and cancer.
Read more